Statera Biopharma, Inc. (STAB)

OTCMKTS: STAB · Delayed Price · USD
0.00 (0.00%)
Feb 23, 2024, 3:21 PM EST - Market closed

Company Description

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis.

The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers.

It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis.

The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021.

Statera Biopharma, Inc. is based in Fort Collins, Colorado.

Statera Biopharma, Inc.
Statera Biopharma logo
Country Colombia
Founded 2013
IPO Date Jul 21, 2006
Industry Biotechnology
Sector Healthcare
Employees 46
CEO Michael Kevin Handley

Contact Details

2537 Research Boulevard, Suite 201
Fort Collins, Colorado 80526
United States
Phone (888) 613-8802

Stock Details

Ticker Symbol STAB
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001318641
CUSIP Number 857561104
ISIN Number US8575611046
Employer ID 20-0077155
SIC Code 2834

Key Executives

Name Position
Michael Kevin Handley Chief Executive Officer, President and Chairman of the Board
Christopher Zosh Executive Vice President of Finance, Interim Principal Financial Officer and Interim Principal Accounting Officer
Dr. Robert W. Buckheit Jr., Ph.D. Chief Technology Officer

Latest SEC Filings

Date Type Title
Mar 3, 2023 25-NSE Filing
Mar 1, 2023 DEFR14A Filing
Feb 27, 2023 DEF 14A Other definitive proxy statements
Feb 14, 2023 PRE 14A Other preliminary proxy statements
Feb 1, 2023 8-K Current Report
Feb 1, 2023 8-A12G Filing
Jan 20, 2023 8-K Current Report
Nov 28, 2022 DEF 14A Other definitive proxy statements
Nov 18, 2022 PRE 14A Other preliminary proxy statements
Nov 15, 2022 8-K Current Report